China Oncology ›› 2025, Vol. 35 ›› Issue (6): 563-569.doi: 10.19401/j.cnki.1007-3639.2025.06.005
• Article • Previous Articles Next Articles
QIAN Fang(), SUN Yongqiang(
), ZHANG Sihan, SONG Tianli
Received:
2025-01-20
Revised:
2025-03-30
Online:
2025-06-30
Published:
2025-07-14
Contact:
SUN Yongqiang
Share article
CLC Number:
QIAN Fang, SUN Yongqiang, ZHANG Sihan, SONG Tianli. Analysis of etiological characteristics, risk factors and inflammatory factors in patients with postoperative infection following modified radical mastectomy[J]. China Oncology, 2025, 35(6): 563-569.
Tab. 1
Distribution of pathogenic bacteria in modified radical mastectomy patients with postoperative infection [n (%)]"
Pathogenic bacteria | Bacterial numbers (n=26) |
---|---|
Staphylococcus aureus | 8 (30.77) |
Enterococcus faecalis | 3 (11.54) |
Staphylococcus epidermidis | 2 (7.69) |
Staphylococcus haemolyticus | 2 (7.69) |
Streptococcus | 1 (3.85) |
E. coli | 4 (15.38) |
Pseudomonas aeruginosa | 3 (11.54) |
Klebsiella pneumoniae | 1 (3.85) |
Acinetobacter baumannii | 1 (3.85) |
Enterobacter cloacae | 1 (3.85) |
Tab. 2
Resistance rate of major Gram-positive pathogens to commonly used antibiotics [n (%)]"
Antibiotics | Staphylococcus aureus | Enterococcus faecalis |
---|---|---|
Penicillin | 7 (87.50) | 3 (100.00) |
Ceftriaxone | 6 (75.00) | 0 (0.00) |
Gentamicin | 1 (12.50) | 2 (66.67) |
Clindamycin | 1 (12.50) | 0 (0.00) |
Levofloxacin | 3 (37.50) | 1 (33.33) |
Tetracycline | 2 (25.00) | 0 (0.00) |
Rifampicin | 1 (12.50) | 0 (0.00) |
Oxacillin | 1 (12.50) | 0 (0.00) |
Vancomycin | 0 (0.00) | 0 (0.00) |
Erythromycin | 1 (12.50) | 0 (0.00) |
Tab. 3
Resistance rate of major Gram-negative pathogens to commonly used antibiotics [n (%)]"
Antibiotics | E. coli | Pseudomonas aeruginosa |
---|---|---|
Penicillin | 4 (100.00) | 3 (100.00) |
Ceftazidime | 3 (75.00) | 3 (100.00) |
Amikacin | 0 (0.00) | 0 (0.00) |
Gentamicin | 2 (50.00) | 2 (66.67) |
Meropenem | 0 (0.00) | 0 (0.00) |
Rifampicin | 0 (0.00) | 0 (0.00) |
Levofloxacin | 1 (25.00) | 1 (33.33) |
Tobramycin | 0 (0.00) | 0 (0.00) |
Lincomycin | 0 (0.00) | 0 (0.00) |
Azithromycin | 0 (0.00) | 1 (33.33) |
Tab. 4
Univariate analysis of surgical incision infection [n (%)]"
Factors | Case n | infection | Non-infection | χ2 value | P value |
---|---|---|---|---|---|
Age/year | 0.196 | 0.658 | |||
≥45 | 82 | 15(18.29) | 67(81.71) | ||
<45 | 46 | 7(15.22) | 39(84.78) | ||
BMI/(kg·m-2) | 2.974 | 0.085 | |||
≥25 | 49 | 12(24.49) | 37(75.51) | ||
<25 | 79 | 10(12.66) | 69(87.34) | ||
Comorbidity | 1.856 | 0.603 | |||
Hypertension | 20 | 5(25.00) | 15(75.00) | ||
Diabetes | 12 | 3(25.00) | 9(75.00) | ||
COPD | 8 | 1(12.50) | 7(87.50) | ||
No | 88 | 13(14.77) | 75(85.23) | ||
TNM stage | 0.603 | 0.437 | |||
Ⅰ | 0 | 0(0.00) | 0(0.00) | ||
Ⅱ | 62 | 9(14.52) | 53(85.48) | ||
Ⅲ | 66 | 13(19.70) | 53(80.30) | ||
Ⅳ | 0 | 0(0.00) | 0(0.00) | ||
Pre-NC | 9.585 | 0.0021 | |||
Yes | 40 | 13(43.33) | 27(67.50) | ||
No | 88 | 9(10.23) | 79(89.77) | ||
ASA grade | 2.916 | 0.233 | |||
Ⅰ | 26 | 7(26.92) | 19(73.08) | ||
Ⅱ | 64 | 11(17.19) | 53(82.81) | ||
Ⅲ | 38 | 4(10.53) | 34(89.47) | ||
Surgery time t/min | 1.179 | 0.278 | |||
≥120 | 68 | 14(20.59) | 54(79.41) | ||
<120 | 60 | 8(13.33) | 52(86.67) | ||
Blood loss V/mL | 11.997 | <0.01 | |||
≥300 | 46 | 15(32.61) | 31(67.39) | ||
<300 | 82 | 7(8.54) | 75(91.46) | ||
Drainage V/mL | 29.024 | <0.01 | |||
≥800 | 34 | 16(47.06) | 18(52.94) | ||
<800 | 94 | 6(6.38) | 88(93.62) | ||
Drain time t/d | 10.951 | <0.01 | |||
≥7 | 58 | 17(29.31) | 41(70.69) | ||
<7 | 70 | 5(7.14) | 65(92.86) | ||
Albumin/(g·L-1) | 7.584 | 0.006 | |||
≥35 | 69 | 6(13.04) | 63(91.30) | ||
<35 | 59 | 16(22.03) | 43(72.88) | ||
WBC/L | 4.269 | 0.039 | |||
≥4×109 | 72 | 8(13.89) | 64(88.89) | ||
<4×109 | 56 | 14(21.43) | 42(75.00) |
Tab. 5
Multivariable logistic regression analysis of surgical incision infection"
Factors | β | S.E. | Wald χ2 | OR | 95% CI | P value |
---|---|---|---|---|---|---|
Pre-NC | 1.614 | 0.388 | 17.266 | 5.021 | 2.345-10.747 | <0.01 |
Blood loss≥300 mL | 1.876 | 0.392 | 22.871 | 6.525 | 3.025-14.075 | <0.01 |
Drainage≥800 mL | 2.758 | 0.430 | 41.121 | 15.769 | 6.787-36.635 | <0.01 |
Drain time≥7 d | 1.998 | 0.421 | 23.575 | 7.376 | 3.292-16.523 | <0.01 |
Albumin<35 g/L | 1.363 | 0.475 | 8.239 | 0.256 | 0.101-0.649 | <0.01 |
WBC<4×109/L | 0.773 | 0.404 | 3.668 | 0.462 | 0.209-1.018 | 0.035 |
Tab. 6
Comparison of serum inflammatory levels before and after surgery between infection and non-infection group"
Group | Case n | PCT/(ng·mL-1) | CRP/(ng·mL-1) | TNF-α/(ng·mL-1) | IL-6/(ng·mL-1) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre-operation | Post-operation | Pre-operation | Post-operation | Pre-operation | Post-operation | Pre-operation | Post-operation | |||||
Infection | 22 | 0.35±0.22 | 5.36±0.74 | 7.24±1.49 | 35.47±5.37 | 0.14±0.08 | 3.17±0.62 | 5.21±0.72 | 25.24±6.83 | |||
Non-infection | 106 | 0.32±0.18 | 2.94±1.92 | 6.78±1.72 | 18.49±4.58 | 0.12±0.04 | 0.85±0.57 | 4.87±0.94 | 12.38±5.64 | |||
t value* | 0.684 | 12.796 | 1.058 | 15.352 | 1.743 | 17.114 | 1.600 | 9.375 | ||||
P value* | 0.495 | <0.001 | 0.292 | <0.001 | 0.084 | <0.001 | 0.112 | < 0.001 |
[1] | QI Y J, SU G H, YOU C, et al. Radiomics in breast cancer: current advances and future directions[J]. Cell Rep Med, 2024, 5(9): 101719. |
[2] | ZHANG H, YANG F, XU Y, et al. Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer[J]. Cell Rep Med, 2025, 6(2): 101924. |
[3] | CHIN K, WÄRNBERG F, KOVACS A, et al. Impact of surgical care bundle on surgical site infection after non-reconstructive breast cancer surgery: a single-centre retrospective comparative cohort study[J]. Cancers (Basel), 2023, 15(3): 919. |
[4] |
中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12): 1092-1187.
doi: 10.19401/j.cnki.1007-3639.2023.12.004 |
The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition)[J]. Chin Oncol, 2023, 33(12): 1092-1187.
doi: 10.19401/j.cnki.1007-3639.2023.12.004 |
|
[5] | SHAN R, DAI L J, SHAO Z M, et al. Evolving molecular subtyping of breast cancer advances precision treatment[J]. Cancer Biol Med, 2024, 21(9): 731-739. |
[6] | 吴淞, 江泽飞. 基于新辅助治疗效果的乳腺癌辅助治疗策略[J]. 中华外科杂志, 2024, 62(2): 104-109. |
WU S, JIANG Z F. Adjuvant therapy strategies for breast cancer based on the efficacy of neoadjuvant therapy[J]. Chin J Surg, 2024, 62(2): 104-109. | |
[7] | DAI L J, MA D, XU Y Z, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer[J]. Nat Commun, 2023, 14(1): 5112. |
[8] | 单娇, 曹煜隆, 杨琳, 等. 北京市乳腺癌根治术后手术部位感染危险因素: 一项多中心前瞻性监测结果[J]. 中国感染控制杂志, 2021, 20(9): 795-800. |
SHAN J, CAO Y L, YANG L, et al. Risk factors for surgical site infection after radical mastectomy for breast cancer in Beijing City: a multi-center prospective surveillance[J]. Chin J Infect Contr, 2021, 20(9): 795-800. | |
[9] | 熊鑫, 刘微微, 应雪艳, 等. 中老年乳腺癌患者术后切口感染分析[J]. 中华老年医学杂志, 2022(6): 700-703. |
XIONG X, LIU W W, YING X Y, et al. Analysis of postoperative wound infections in middle-aged and elderly patients with breast cancer[J]. Chin J Geriatr, 2022(6): 700-703. | |
[10] | 李鹍鹏, 杜新峰, 刘平贤, 等. 乳腺癌术后切口感染病原菌及其影响因素[J]. 中华医院感染学杂志, 2022, 32(20): 3128-3131. |
LI K P, DU X F, LIU P X, et al. Pathogenic bacteria and its influencing factors of postoperative incision infection in breast cancer patients[J]. Chin J Nosocomiol, 2022, 32(20): 3128-3131. | |
[11] | XIE X Q, YANG Y, WANG Q, et al. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria[J]. Cell Res, 2023, 33(3): 215-228. |
[12] | AL-HILLI Z, WILKERSON A. Breast surgery: management of postoperative complications following operations for breast cancer[J]. Surg Clin North Am, 2021, 101(5): 845-863. |
[13] | 袁忠, 马海南, 王科军. 改良根治术与保乳手术对早期乳腺癌的临床效果、术后并发症及生活质量的影响分析[J]. 湖南师范大学学报(医学版), 2022, 19(4): 88-91. |
YUAN Z, MA H N, WANG K J. Clinical effect, postoperative complications and quality of life of modified radical mastectomy and breast-conserving surgery on early breast cancer[J]. J Hunan Norm Univ Med Sci, 2022, 19(4): 88-91. | |
[14] | LORENTZEN T, HEIDEMANN L N, MÖLLER S, et al. Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2022, 48(1): 44-52. |
[15] | 牛海娜, 贾瑛, 张娜. 骨科患者术后感染危险因素及围术期血清C反应蛋白、白蛋白水平监测价值分析[J]. 实用医院临床杂志, 2021, 18(4): 64-67. |
NIU H N, JIA Y, ZHANG N. The risk factors for postoperative infection in orthopedic patients and the significance of monitoring perioperative serum CRP and ALB levels[J]. Pract J Clin Med, 2021, 18(4): 64-67. | |
[16] | 董马锋, 李永刚. 乳腺癌改良根治术后切口感染患者的降钙素原、C反应蛋白、凝血功能指标变化及临床意义[J]. 血栓与止血学, 2022, 28(3): 1002-1004. |
DONG M F, LI Y G. Changes and clinical significance of procalcitonin, C reactive protein and coagulation function in patients with incision infection after modified radical mastectomy[J]. Chin J Thromb Hemostasis, 2022, 28(3): 1002-1004. | |
[17] | 程双蕾, 李征, 刘磊, 等. 根治性膀胱癌切除术后感染切口愈合的危险因素[J]. 中华医院感染学杂志, 2021, 31(5): 677-680. |
CHENG S L, LI Z, LIU L, et al. Risk factors for healing of postoperative incision infection in radical bladder cancer resection patients[J]. Chin J Nosocomiol, 2021, 31(5): 677-680. | |
[18] | 刘大响, 王令焕, 徐梅, 等. 头颈恶性肿瘤术后切口感染影响因素及CRP与sTREM-1和IL-6水平[J]. 中华医院感染学杂志, 2022, 32(3): 430-433. |
LIU D X, WANG L H, XU M, et al. Influencing factors for postoperative incision infection and sTREM-1, IL-6 of patients with head and neck malignant tumors[J]. Chin J Nosocomiol, 2022, 32(3): 430-433. |
[1] | ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong. Research progress in epidemiology and risk factors of thyroid cancer [J]. China Oncology, 2025, 35(1): 21-29. |
[2] | TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong. Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor [J]. China Oncology, 2023, 33(5): 478-483. |
[3] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
[4] | LIU Jiawei, LI Dan, ZHAI Qing. Risk factors analysis of liver injury induced by chemotherapy in patients with breast cancer [J]. China Oncology, 2021, 31(1): 52-62. |
[5] | DING Pingan, YANG Peigang, TIAN Yuan, GUO Ziyang, GUO Honghai, LIU Yang, ZHANG Zhidong, WANG Dong, LI Yong, ZHAO Qun. Effect of extranodal invasion on survival and prognosis of gastric cancer patients: a report of 2 386 cases [J]. China Oncology, 2020, 30(12): 1017-1025. |
[6] | MA Xiaokai,HUANG Jiankang,ZHU Bo,PENG Defeng,ZHOU Rui,WANG Shengying . Clinical characteristics of papillary thyroid microcarcinoma and risk factors for cervical lymph node metastasis: a clinical analysis of 228 cases [J]. China Oncology, 2019, 29(8): 590-594. |
[7] | MIAO Changfeng,MA Yuntao,WANG Xiaopeng,HU Ming,YANG Xiaojun . Construction of the risk factor model of gastric cancer and its value in screening opportunity and options [J]. China Oncology, 2019, 29(7): 501-507. |
[8] | LIU Shan, FANG Juan, WANG Lili, ZHANG Yinghong, DU Wenjie, ZHU Taohua. Association between peripheral nerve invasion and recurrence risk factors in cervical cancer [J]. China Oncology, 2019, 29(6): 439-444. |
[9] | LIU Xiaoxue, YU Chuanhua, ZHOU Wei, et al. Trends in colorectal cancer mortality for the last 30 years in China [J]. China Oncology, 2018, 28(3): 177-183. |
[10] | LIN Xuedan, YANG Tianxing,TAO Zhihua. Predictive value of CEA and CA19-9 for recurrence in stage Ⅱ-Ⅲ colon cancer [J]. China Oncology, 2018, 28(11): 827-832. |
[11] | WANG Hao, JIANG Wenjie, MA Tieliang, et al. Post-operative analgesic efficacy and safety of ultrasound-guided thoracic paravertebral block and serratus plane block on modified radical mastectomy [J]. China Oncology, 2018, 28(10): 776-779. |
[12] | LIN Zhenhai, YAN Shican, ZHANG Jieyun, et al. MST4 upregulates secretion of inflammatory factors via activation of MAPK-ERK signaling pathway and promotes invasion and metastasis of hepatocellular carcinoma [J]. China Oncology, 2017, 27(9): 681-686. |
[13] | LI Min, XIE Ming. Advances in research on multiple primary malignant tumors [J]. China Oncology, 2017, 27(2): 156-160. |
[14] | SHEN Lihua, ZHANG Zhongwei, ZHU Biao. Clinical analysis of tumor related venous thromboembolism: 196 cases [J]. China Oncology, 2016, 26(4): 338-345. |
[15] | DONG Fen, ZHANG Biao, SHAN Guangliang. Distribution and risk factors of thyroid cancer in China [J]. China Oncology, 2016, 26(1): 47-52. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd